Key result
Secondary pulmonary hypertension documentation in HCM decedents rose ~7% annually from 2003 to 2020.
Why the study?
Hypertrophic cardiomyopathy is associated with diastolic dysfunction and elevated left atrial pressures that may lead to secondary pulmonary hypertension, but population-level data on pulmonary hypertension trends and demographic patterns among hypertrophic cardiomyopathy decedents were limited.
Observational (n=40,897)
Yes
Co-documentation of secondary pulmonary hypertension among U.S. decedents with hypertrophic cardiomyopathy increased significantly from 2003 to 2020 and is strongly associated with older age, female sex, and death in institutional settings.
Answers are grounded in this paper and cite their sources.
Rising secondary PH co-documentation in HCM deaths, especially older females, supports awareness; leaves open whether trends reflect true incidence or coding changes.
Background Hypertrophic cardiomyopathy (HCM) is associated with diastolic dysfunction and elevated left atrial pressures that may lead to secondary pulmonary hypertension (PH). Population-level data on PH trends among HCM decedents remain limited. Purpose To characterise the temporal trends and demographic patterns of secondary PH among U.S. decedents with HCM. Methods Using the CDC WONDER multiple-cause-of-death database (1999–2020), we identified decedents with HCM (ICD-10: I42.1, I42.2) as underlying cause and secondary PH (I27.2) as contributing cause. Age-adjusted mortality rates were standardised to the 2000 U.S. population. Joinpoint regression estimated annual percent change (APC) with 95% confidence intervals. Trend analysis was restricted to 2003–2020 due to suppressed cell counts (<10 deaths) in earlier years. Chi-square tests compared demographic distributions. Sensitivity analysis excluded 2020 to assess pandemic effects. Results Among 40,897 HCM decedents from 1999–2020, 798 (1.95%) had documented secondary PH. The proportion increased significantly from 2003 to 2020 (APC 7.35%, 95% CI 6.08–8.97; p<0.001), with no inflection points identified. In contrast, HCM age-adjusted mortality rates declined from 2003–2014 (APC −5.41%, p<0.05) and plateaued thereafter. Findings remained consistent after exclusion of 2020. The proportion of HCM decedents with PH increased significantly across age strata (χ² for trend = 357.8, p<0.001), rising from 0.35% among individuals aged 15–24 years to 3.70% among those ≥85 years. The mean age of HCM+PH decedents was 73.5 ± 15.3 years. HCM+PH decedents were more frequently female compared with HCM-only decedents (71.8% vs 42.3%; χ² = 276.7, df = 1, p<0.001). Racial distribution differed significantly between groups (χ² = 6.91, df = 2, p = 0.031). The proportion of HCM decedents with documented PH was highest among White individuals (2.04%), followed by Asian/Pacific Islander (1.91%) and Black/African American decedents (1.56%). PH documentation also differed by Hispanic ethnicity (χ² = 12.62, df = 1, p<0.001), with lower representation among Hispanic decedents (1.09%) compared with non-Hispanic decedents (2.02%). Place of death differed significantly between groups (χ²=185.9, df=4, p<0.001). Compared with HCM-only decedents, HCM+PH decedents were more likely to die in hospital or institutional settings such as hospice and nursing/long-term care facilities, and substantially less likely to die at home. Conclusion Secondary PH is increasingly documented among HCM decedents and is associated with older age, female sex, and institutional death. These observational findings do not establish causality, but suggest a later-stage HCM phenotype and warrant prospective imaging studies to clarify underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Shanmuganathan et al. (2026) conducted an observational in Hypertrophic cardiomyopathy (HCM) decedents with and without secondary pulmonary hypertension (PH) (n=40,897). Co-documented secondary pulmonary hypertension (ICD-10: I27.2) vs. HCM-only decedents without documented secondary pulmonary hypertension was evaluated on Proportion and temporal trend (annual percent change) of documented secondary pulmonary hypertension among HCM decedents (APC 7.35%, 95% CI 6.08-8.97, p=<0.001). Secondary pulmonary hypertension co-documentation occurred in 1.95% of HCM decedents and increased from 2003 to 2020.
Synapse has enriched 10 related papers. Consider them for comparative context: